<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501861</url>
  </required_header>
  <id_info>
    <org_study_id>20-301</org_study_id>
    <nct_id>NCT04501861</nct_id>
  </id_info>
  <brief_title>Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients:</brief_title>
  <official_title>Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients: a Comparative-effectiveness Quality Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The relative increase in the mPAP with the same unit increase in MAP adjusted for baseline,&#xD;
      and RV function assessed by GLS, between VP and NE in patients with normal and increased&#xD;
      pulmonary artery pressure, who require vasopressor support during cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of our study are to compare 1) the relative increase in the mPAP with the&#xD;
      same unit increase in MAP adjusted for baseline and 2) RV function assessed by GLS, between&#xD;
      VP and NE in patients with normal and increased pulmonary artery pressure, who require&#xD;
      vasopressor support during cardiac surgery. We hypothesize that the use of vasopressin&#xD;
      compared with norepinephrine induces a lower mPAP-to-MAP ratio, in cardiac surgical patients&#xD;
      with and without pulmonary hypertension who require intraoperative vasopressor support.&#xD;
      Second, we will test the hypothesis that vasopressin is associated with improved right&#xD;
      ventricular global longitudinal strain compared to norepinephrine in patients requiring&#xD;
      vasopressor support during cardiac surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Anticipated">February 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mPAP-to-MAP ratio between patients who received norepinephrine versus vasopressin intraoperatively.</measure>
    <time_frame>during surgery</time_frame>
    <description>Compare mPAP-to-MAP ratio between patients who received norepinephrine versus vasopressin intraoperatively. Post intervention measurements will be recorded after protamine administration until end of chest closure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cardiac Disease</condition>
  <arm_group>
    <arm_group_label>The use of vasopressin compared with norepinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigator hypothesize that the use of vasopressin compared with norepinephrine induces a lower mPAP-to-MAP ratio, in cardiac surgical patients with and without pulmonary hypertension who require intraoperative vasopressor support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The use of norepinephrine compared with vasopressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigators will compare GLS between patients who received norepinephrine versus vasopressin intraoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Hemodynamic effect of norepinephrine on the pulmonary circulation in cardiac surgery patients</description>
    <arm_group_label>The use of norepinephrine compared with vasopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>Hemodynamic effect of vasopressin on the pulmonary circulation in cardiac surgery patients</description>
    <arm_group_label>The use of vasopressin compared with norepinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Adults&gt; 18 years of age&#xD;
&#xD;
          -  Elective cardiac surgery with the use of CPB&#xD;
&#xD;
          -  Patients with pulmonary artery catheter insertion&#xD;
&#xD;
          -  Systemic hypotension (MAP &lt; 70 mmHg) requiring continuous infusion of vasopressor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Transplant surgery&#xD;
&#xD;
          -  Ventricular assist device implantation other than intra-aortic balloon&#xD;
             counter-pulsation&#xD;
&#xD;
          -  Pulmonary endarterectomy&#xD;
&#xD;
          -  Thoracoabdominal aneurysm repair&#xD;
&#xD;
          -  Inhalational pulmonary vasodilators (e.g. Epoprostenol) administration before&#xD;
             insertion of pulmonary artery catheter&#xD;
&#xD;
          -  Vasopressin is started as the first choice of pressor per clinical staff discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariya Geube, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberta Johnson</last_name>
    <phone>216-444-9950</phone>
    <email>johnsor13@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meriya Geube, MD</last_name>
      <phone>216-444-2779</phone>
      <email>greubem@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Roberta Johnson</last_name>
      <phone>216-444-9950</phone>
      <email>johnsor13@ccf.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

